CRH Provides Partnership Program Update
Investor Contact: Dean Linden 604.633.1440
VANCOUVER, BC, February 24, 2009 ‘ CRH Medical Corporation announced today that through its Partnership Program, the CRH O’Regan Hemorrhoid banding technology has been adopted by more than 90% of the gastroenterologist practice groups trained by the Company since June 2008.’ The Company believes this provides clear evidence of not only a strong medical need, but also confirmation of the consistency of its training methodology.’ The sharing of knowledge and experience from our CRH Centers for Colorectal Health to individual physicians through our Partnership Program has gone smoothly, with continued high levels of safety and successful treatment outcomes.
The Company has now trained over two hundred physicians representing over 40 practice groups in 30 markets across the United States. The diagnosis of hemorrhoids requiring treatment during colonoscopy is very common. The CRH technology provides physicians with an effective modality to treat hemorrhoidal disease.’ It is clear by the significant adoption rate amongst physicians that the treatment of hemorrhoids is a natural extension of their practice.’ With over 8,000 gastroenterologists in the U.S. alone, the Company expects to significantly increase its efforts under the Partnership Program.
Commenting on the success of the Partnership Program, Edward Wright, Chief Executive of CRH said, ‘I am delighted to report that our new physician partners are reporting the same outstanding clinical outcomes that we experienced in treating over 50,000 hemorrhoids in our own Centers in the U.S.’ Wright further stated, ‘The Company expects to train in excess of 75 physicians in approximately 20 practices groups during the first quarter of 2009.’
About CRH Medical Corporation:
CRH Medical Corporation specializes in the treatment of hemorrhoids utilizing its proven treatment protocol and patented proprietary technology. CRH’s single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I ‘ IV. CRH Medical employs two commercialization strategies: First, it operates Centers for Colorectal Health facilities in the United States specializing in the treatment of hemorrhoids and fissures, and colon cancer screening. In addition CRH distributes its hemorrhoid banding technology, treatment protocols, operational and marketing expertise as a complete, “turn key” package directly to its partner physicians. The Company’s goal is to establish the CRH hemorrhoid technology as the standard for hemorrhoid treatment.
The information in this news release contains so-called ‘forward-looking’ statements. These include statements regarding CRH Medical expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as ‘anticipate’, ‘expect’, ‘intend’, ‘plan’, ‘will’, ‘we believe’, ‘CRH Medical believes’, ‘management believes’ and similar language. All forward-looking statements are based on CRH Medical current expectations and are subject to risks and uncertainties and to assumptions made.
For further information call Dean Linden, Corporate Communications, CRH Medical Corporation at 604.633.1440 or firstname.lastname@example.org. Additional information may also be found by visiting the Company’s website at www.crhmedcorp.com or the SEDAR website at www.sedar.com.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.